Literature DB >> 21327796

Effects of β2-adrenergic stimulation on exercise capacity in normal subjects.

S P Beloka1, C Janssen, E Woff, E Brassine, G Deboeck, J Randria, V Philippart de Foy, P van de Borne, R Naeije.   

Abstract

β2-Adrenergic receptor agonists are believed to present with ergogenic properties. However, how combined respiratory, cardiovascular and muscular effects of these drugs might affect exercise capacity remain incompletely understood. The effects of salbutamol were investigated in 23 healthy subjects. The study was randomised, placebo-controlled in double-blind and followed a cross-over design. Salbutamol was given at the dose of 10 μg/min in 11 subjects and 20 μg/min iv in the other 12 subjects. Measurements included muscle sympathetic nerve activity (MSNA), ventilatory responses to hyperoxic hypercapnia (7% CO(2) in O(2,) central chemoreflex), isocapnic hypoxia (10% O(2) in N(2), peripheral chemoreflex) and isometric muscle contraction followed by a local circulatory arrest (metaboreflex), cardiopulmonary exercise test (CPET) variables and isokinetic muscle strength. Salbutamol 10 μg/min increased heart rate and blood pressure, while MSNA burst frequency remained unchanged. Peripheral chemosensitivity increased, as evidenced by an increased ventilatory response to hypoxia, but ventilatory responses to hypercapnia or muscle ischaemia remained unchanged. The effects of salbutamol 20 μg/min were similar. Both doses of salbutamol did not affect CPET. Only the higher dose of salbutamol decreased the anaerobic threshold, but this was not associated with a change in VO(2) max. Salbutamol increased the slopes of ventilation as a function of VO(2) (P < 0.05) and VCO(2) (P < 0.001) during CPET. Maximal isokinetic muscle strength was not affected by salbutamol. In conclusion, the acute administration of either low or high dose salbutamol does not affect exercise capacity in normal subjects, in spite of an earlier anaerobic threshold and increased chemosensitivity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21327796     DOI: 10.1007/s00421-011-1856-9

Source DB:  PubMed          Journal:  Eur J Appl Physiol        ISSN: 1439-6319            Impact factor:   3.078


  54 in total

1.  The effect of inhaled salbutamol and salmeterol on lung function and endurance performance in healthy well-trained athletes.

Authors:  K H Carlsen; F Ingjer; H Kirkegaard; B Thyness
Journal:  Scand J Med Sci Sports       Date:  1997-06       Impact factor: 4.221

Review 2.  The Na+, K+ pump in skeletal muscle: quantification, regulation and functional significance.

Authors:  T Clausen
Journal:  Acta Physiol Scand       Date:  1996-03

3.  Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a beta 2-receptor agonist.

Authors:  R J Zeman; R Ludemann; T G Easton; J D Etlinger
Journal:  Am J Physiol       Date:  1988-06

4.  Effect of isoproterenol on amino acid levels and protein turnover in skeletal muscle.

Authors:  J B Li; L S Jefferson
Journal:  Am J Physiol       Date:  1977-02

5.  Effect of intravenous infusion of salbutamol on ventilatory response to carbon dioxide and hypoxia and on heart rate and plasma potassium in normal men.

Authors:  A G Leitch; L J Clancy; J F Costello; D C Flenley
Journal:  Br Med J       Date:  1976-02-14

6.  Acute effects of inhaled salbutamol on the metabolic rate of normal subjects.

Authors:  P Amoroso; S R Wilson; J Moxham; J Ponte
Journal:  Thorax       Date:  1993-09       Impact factor: 9.139

7.  Mechanisms by which systemic salbutamol increases ventilation.

Authors:  Antony E Tobin; Anne-Marie Pellizzer; John D Santamaria
Journal:  Respirology       Date:  2006-03       Impact factor: 6.424

8.  Dobutamine potentiates arterial chemoreflex sensitivity in healthy normal humans.

Authors:  Sonia Velez-Roa; Baktybek Kojonazarov; Agnieszka Ciarka; Pascal Godart; Robert Naeije; Virend K Somers; Philippe van de Borne
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-05-15       Impact factor: 4.733

9.  Effects of clenbuterol and salbutamol on tissue rubidium uptake in vivo.

Authors:  J Cartañà; M J Stock
Journal:  Metabolism       Date:  1995-01       Impact factor: 8.694

10.  Beta-adrenergic blockade and metabo-chemoreflex contributions to exercise capacity.

Authors:  Sofia Beloka; Marko Gujic; Gael Deboeck; Georges Niset; Agnieszka Ciarka; Jean-François Argacha; Dionysios Adamopoulos; Philippe Van de Borne; Robert Naeije
Journal:  Med Sci Sports Exerc       Date:  2008-11       Impact factor: 5.411

View more
  3 in total

1.  Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes.

Authors:  Rebecca L Scalzo; Kerrie L Moreau; Cemal Ozemek; Leah Herlache; Shawna McMillin; Sarah Gilligan; Amy G Huebschmann; Tim A Bauer; Jennifer Dorosz; Jane E B Reusch; Judith G Regensteiner
Journal:  J Diabetes Complications       Date:  2016-10-07       Impact factor: 2.852

2.  Safety of bronchodilator reversibility test in elderly subjects: a prospective study.

Authors:  Anna Dor-Wojnarowska; Anna Parużyńska; Aleksandra Kulczak; Marta Majewska-Pulsakowska; Małgorzata Szymala-Pędzik; Zbigniew Machaj; Małgorzata Sobieszczańska; Małgorzata Poręba
Journal:  Postepy Dermatol Alergol       Date:  2020-02-19       Impact factor: 1.837

3.  Exercise performance after salbutamol inhalation in non-asthmatic, non-athlete individuals: a randomised, controlled, cross-over trial.

Authors:  Filip Eckerström; Christian Emil Rex; Marie Maagaard; Sune Rubak; Vibeke Elisabeth Hjortdal; Johan Heiberg
Journal:  BMJ Open Sport Exerc Med       Date:  2018-08-30
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.